55 Clinically Relevant NSCLC Models with Key Mutations & Molecular Characteristics
Optimize the development of your Non Small Cell Lung Cancer (NSCLC) treatments with our premier in vivo screening platform. This platform includes a meticulously curated collection of 55 patient-derived xenograft (PDX) models, both pretreated and treatment-naïve, reflecting real-world responses to therapies such as checkpoint inhibitors and EGFR-targeted treatments.
Clinically Relevant Models
Living bank of 55 clinically relevant PDX models with key mutations and molecular characteristics.
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' leading NSCLC In Vivo Screen showcases 55 PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Includes Non-Small Cell Lung Cancer models pretreated with advanced cancer therapies such as EGFR-targeted therapies and check point inhibitors.
-
Includes models with crucial mutations such as EGFR and KRAS Mutant Models.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
-
Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
-
Terminal tumor collections for target validation is available upon request (Snap Frozen/FFPE)
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)
Figure 1: Correlation between the results obtained from the NSCLC In Vivo Screen PDX model, developed from a primary lung tumor, and the patient's clinical response from the tumor.